$4.53
0.33% yesterday
Nasdaq, May 20, 09:49 pm CET
ISIN
US75629V1044
Symbol
RXRX
Sector
Industry

Recursion Pharmaceuticals Stock price

$4.55
-0.86 15.90% 1M
-1.49 24.67% 6M
-2.21 32.69% YTD
-5.23 53.48% 1Y
-0.86 15.90% 3Y
-26.75 85.46% 5Y
-26.75 85.46% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.04 0.89%
ISIN
US75629V1044
Symbol
RXRX
Sector
Industry

Key metrics

Market capitalization $1.85b
Enterprise Value $1.44b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 24.07
P/S ratio (TTM) P/S ratio 30.93
P/B ratio (TTM) P/B ratio 1.98
Revenue growth (TTM) Revenue growth 29.32%
Revenue (TTM) Revenue $59.79m
EBIT (operating result TTM) EBIT $-574.03m
Free Cash Flow (TTM) Free Cash Flow $-397.71m
Cash position $503.53m
EPS (TTM) EPS $-1.78
P/E forward negative
P/S forward 26.16
EV/Sales forward 20.36
Short interest 24.71%
Show more

Is Recursion Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Recursion Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Recursion Pharmaceuticals forecast:

2x Buy
29%
5x Hold
71%

Analyst Opinions

7 Analysts have issued a Recursion Pharmaceuticals forecast:

Buy
29%
Hold
71%

Financial data from Recursion Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
60 60
29% 29%
100%
- Direct Costs 83 83
30% 30%
138%
-23 -23
33% 33%
-38%
- Selling and Administrative Expenses 153 153
88% 88%
256%
- Research and Development Expense 350 350
40% 40%
585%
-526 -526
51% 51%
-879%
- Depreciation and Amortization 49 49
27% 27%
81%
EBIT (Operating Income) EBIT -574 -574
48% 48%
-960%
Net Profit -575 -575
62% 62%
-961%

In millions USD.

Don't miss a Thing! We will send you all news about Recursion Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Recursion Pharmaceuticals Stock News

Positive
The Motley Fool
9 days ago
Artificial intelligence (AI) has taken over Wall Street. The leaders in this rapidly growing field are attracting significant attention.
Positive
The Motley Fool
10 days ago
The artificial intelligence (AI) revolution is reshaping our world at an unprecedented pace. As AI technology evolves, it's set to fundamentally transform countless industries through enhanced automation, operational efficiency, and dramatic improvements in workforce productivity.
Negative
The Motley Fool
11 days ago
Shares of Recursion Pharmaceuticals (RXRX -1.48%) fell this week. The stock lost 24% as of market close on Friday.
More Recursion Pharmaceuticals News

Company Profile

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Chistopher Gibson
Founded 2013
Website www.recursion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today